Hui, Daphne
Murgai, Aditya A.
Gilmore, Greydon
Mohideen, Shabna I.
Parrent, Andrew G.
Jog, Mandar S.
Article History
Received: 6 December 2019
Accepted: 6 April 2020
First Online: 19 May 2020
Competing interests
: Daphne Hui received graduate funding from Mitacs, in collaboration with Boston Scientific. Dr. Aditya A Murgai declares no competing interests. Greydon Gilmore received graduate funding from Mitacs. Shabna I Mohideen received graduate funding from Mitacs, in collaboration with Boston Scientific. Dr. Andrew Parrent received an honorarium from Boston Scientific. Dr. Mandar S Jog receives research grants from Boston Scientific. Dr. Jog also receives speaker honoraria fees and serves on advisory boards including Merz Pharma, Allergan Inc., Abbvie and Valeo Pharma. Dr. Jog also receives grants from Mitacs, OCE, Research Council of Norway, Parkinson Society Canada, Parkinson Society Southwestern Ontario and AMOSO. Dr. Jog has financial interests in Manjog Enterprises Limited and MDDT Inc. There is no conflict with any of these with the research presented in this manuscript.